November 29, 2016 - By Vivian Park
The company have set target price per share of GBX 137.00 on Synairgen PLC (LON:SNG) shares. This is 844.83% from the last stock price. In a note issued on 29 November, finnCap maintained their “Corporate” rating on shares of SNG.
Out of 2 analysts covering Synairgen PLC (LON:SNG), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 137 is the highest target while GBX 46 is the lowest. The GBX 91.50 average target is 553.10% above today’s (GBX 14.01) stock price. Synairgen PLC has been the topic of 12 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Corporate” rating by FinnCap given on Tuesday, August 30. The firm has “Buy” rating by N+1 Singer given on Wednesday, August 5. The firm has “Buy” rating by N+1 Singer given on Thursday, September 22. The stock of Synairgen plc (LON:SNG) has “Buy” rating given on Wednesday, September 16 by N+1 Singer. The rating was maintained by FinnCap on Thursday, September 22 with “Corporate”. The rating was maintained by FinnCap on Wednesday, August 5 with “Corporate”. On Wednesday, October 12 the stock rating was maintained by FinnCap with “Corporate”. The firm has “Buy” rating given on Thursday, January 28 by N+1 Singer. N+1 Singer maintained the shares of SNG in a report on Wednesday, July 22 with “Buy” rating. The firm earned “Corporate” rating on Tuesday, November 17 by FinnCap.
About 5,000 shares traded hands. Synairgen plc (LON:SNG) has declined 60.00% since April 28, 2016 and is downtrending. It has underperformed by 65.26% the S&P500.
Synairgen plc is a holding company. The Firm is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (IPF). The company has a market cap of 13.15 million GBP. The Firm uses its human biology BioBank platform to discover and develop therapies for respiratory disease. It currently has negative earnings. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.
More news for Synairgen plc (LON:SNG) were recently published by: Fool.Co.Uk, which released: “Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?” on June 07, 2016. Reuters.com‘s article titled: “BRIEF-Synairgen says AstraZeneca decided to stop phase IIa AZD9412 trial” and published on October 12, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park